Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

Natasha K. Martin; Peter Vickerman; Alec Miners; Graham R. Foster; Sharon Hutchinson; David Goldberg; Matthew Hickman

doi:10.1002/hep.24656

Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

Natasha K. Martin, Peter Vickerman, Alec Miners, Graham R. Foster, Sharon Hutchinson, David Goldberg, Matthew Hickman

SHLS School Office

Research output: Contribution to journal › Article › peer-review

Abstract

Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon-a + ribavirin) has been shown to be cost-effective for patients with no reinfection risk. We examined the cost-effectiveness of providing antiviral treatment for injecting drug users (IDUs) as compared with treating ex/non-IDUs or no treatment.

Original language	English
Pages (from-to)	49-57
Number of pages	9
Journal	Hepatology
Volume	55
Issue number	1
Early online date	6 Dec 2011
DOIs	https://doi.org/10.1002/hep.24656
Publication status	Published - Jan 2012

Keywords

hepatitis C
antiviral treatment
intravenous drug users
reinfection risk

Documents and Links

10.1002/hep.24656

Publication in Scopus

Fingerprint Dive into the research topics of 'Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations'. Together they form a unique fingerprint.

Cite this

@article{386657f9c6e44ec19a4e66ca46c47cc0,

title = "Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations",

abstract = "Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon-a + ribavirin) has been shown to be cost-effective for patients with no reinfection risk. We examined the cost-effectiveness of providing antiviral treatment for injecting drug users (IDUs) as compared with treating ex/non-IDUs or no treatment. ",

keywords = "hepatitis C, antiviral treatment, intravenous drug users, reinfection risk",

author = "Martin, {Natasha K.} and Peter Vickerman and Alec Miners and Foster, {Graham R.} and Sharon Hutchinson and David Goldberg and Matthew Hickman",

year = "2012",

month = jan,

doi = "10.1002/hep.24656",

language = "English",

volume = "55",

pages = "49--57",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "1",

}

TY - JOUR

T1 - Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

AU - Martin, Natasha K.

AU - Vickerman, Peter

AU - Miners, Alec

AU - Foster, Graham R.

AU - Hutchinson, Sharon

AU - Goldberg, David

AU - Hickman, Matthew

PY - 2012/1

Y1 - 2012/1

N2 - Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon-a + ribavirin) has been shown to be cost-effective for patients with no reinfection risk. We examined the cost-effectiveness of providing antiviral treatment for injecting drug users (IDUs) as compared with treating ex/non-IDUs or no treatment.

AB - Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon-a + ribavirin) has been shown to be cost-effective for patients with no reinfection risk. We examined the cost-effectiveness of providing antiviral treatment for injecting drug users (IDUs) as compared with treating ex/non-IDUs or no treatment.

KW - hepatitis C

KW - antiviral treatment

KW - intravenous drug users

KW - reinfection risk

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84155180685&partnerID=8YFLogxK

U2 - 10.1002/hep.24656

DO - 10.1002/hep.24656

M3 - Article

AN - SCOPUS:84155180685

VL - 55

SP - 49

EP - 57

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -